ACC 2026
This is the logo of the provider
ACC 2206 28 - 30 March 2026

Effect of oral semaglutide versus placebo on first and total MACE in SOUL trial participants with T2D and ASCVD and/or CKD

Authors :

Nikolaus Marx1*; John E. Deanfield2*; Sharon L. Mulvagh3†; Silvio E. Inzucchi4; Rodica Pop-Busui5; Johannes F. E. Mann6,7; Neil R. Poulter8; G. Kees Hovingh9; Alex Videmark9; Zaklina Davicevic-Elez9; Derrick Musinga10; John B. Buse11; on behalf of the SOUL Study Group
Affiliations
View Details Hide Details
Download poster (.pdf)
Keywords
Diabetes
Congress poster
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)